LifeMD announces a cash dividend of $0.5546875 per share for its Series A preferred stock, payable January 15, 2026.
Quiver AI Summary
LifeMD, Inc. has announced the declaration of a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock, which will be paid on January 15, 2026, to shareholders on record as of January 5, 2026. The company, a provider of virtual primary care and pharmacy solutions, utilizes a comprehensive digital care platform and an affiliated medical group to deliver healthcare services across various conditions. The release also includes cautionary notes about forward-looking statements regarding the company's financial outlook and operations, emphasizing the uncertainty and risks involved that could affect future performance.
Potential Positives
- Declaration of a cash dividend of $0.5546875 per share for preferred stockholders, demonstrating financial strength and commitment to returning value to investors.
- The dividend payout reflects confidence in the company's ongoing performance and stability, which may enhance investor trust and attract new investors.
- Payment of the dividend on January 15, 2026, provides an incentive for current and potential investors to hold onto their shares, thereby supporting the stock price.
Potential Negatives
- The announcement of the preferred dividend may raise concerns among investors about the company's cash flow and financial stability, as it implies that the company is prioritizing dividend payments over other potential reinvestments or debt repayments.
- The forward-looking statements highlight uncertainties and risks regarding the company’s future performance and financial condition, indicating that stakeholders should be cautious about the reliability of such projections.
- The ongoing legal and regulatory risks mentioned may cast doubt on the company’s ability to operate efficiently and comply with evolving regulations, potentially impacting investor confidence.
FAQ
What dividend has LifeMD authorized for its preferred stock?
LifeMD has authorized a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock.
When will the LifeMD preferred dividend be paid?
The preferred dividend will be paid on January 15, 2026.
What is the record date for the LifeMD dividend?
The record date for the LifeMD dividend is January 5, 2026.
What services does LifeMD offer?
LifeMD provides virtual primary care, telemedicine, laboratory access, pharmacy services, and treatment for over 200 conditions.
How can I contact LifeMD for investor or media inquiries?
For investor inquiries, contact Marc Benathen at [email protected]. For media inquiries, contact Jessica Friedeman at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LFMD Insider Trading Activity
$LFMD insiders have traded $LFMD stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $LFMD stock by insiders over the last 6 months:
- JUSTIN SCHREIBER (Chairman and CEO) has made 0 purchases and 2 sales selling 50,000 shares for an estimated $584,147.
- NICHOLAS P ALVAREZ (Chief Acquisition Officer) sold 75,000 shares for an estimated $443,760
- JESSICA FRIEDEMAN (Chief Marketing Officer) sold 15,000 shares for an estimated $54,157
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LFMD Revenue
$LFMD had revenues of $60.2M in Q3 2025. This is an increase of 12.95% from the same period in the prior year.
You can track LFMD financials on Quiver Quantitative's LFMD stock page.
$LFMD Hedge Fund Activity
We have seen 57 institutional investors add shares of $LFMD stock to their portfolio, and 92 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. removed 925,685 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $6,285,401
- D. E. SHAW & CO., INC. removed 775,284 shares (-63.6%) from their portfolio in Q3 2025, for an estimated $5,264,178
- CITADEL ADVISORS LLC added 657,824 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,466,624
- MORGAN STANLEY removed 617,525 shares (-38.8%) from their portfolio in Q3 2025, for an estimated $4,192,994
- RENAISSANCE TECHNOLOGIES LLC added 547,625 shares (+50.4%) to their portfolio in Q3 2025, for an estimated $3,718,373
- JUMP FINANCIAL, LLC removed 467,652 shares (-90.8%) from their portfolio in Q3 2025, for an estimated $3,175,357
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 434,937 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,953,222
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LFMD Analyst Ratings
Wall Street analysts have issued reports on $LFMD in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/19/2025
- Keybanc issued a "Overweight" rating on 11/19/2025
- BTIG issued a "Buy" rating on 11/18/2025
- Lake Street issued a "Buy" rating on 11/18/2025
- B. Riley Securities issued a "Buy" rating on 11/18/2025
To track analyst ratings and price targets for $LFMD, check out Quiver Quantitative's $LFMD forecast page.
$LFMD Price Targets
Multiple analysts have issued price targets for $LFMD recently. We have seen 8 analysts offer price targets for $LFMD in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Steve Dechert from Keybanc set a target price of $8.0 on 11/19/2025
- Steven Valiquette from Mizuho set a target price of $6.0 on 11/19/2025
- Yi Chen from HC Wainwright & Co. set a target price of $9.0 on 11/19/2025
- Brooks O'Neil from Lake Street set a target price of $8.0 on 11/18/2025
- David Larsen from BTIG set a target price of $10.0 on 11/18/2025
- William Woods from B. Riley Securities set a target price of $10.0 on 11/18/2025
Full Release
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.
The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026.
About LifeMD, Inc.
LifeMD
®
is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, spanning primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit
LifeMD.com
.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Marc Benathen, Chief Financial Officer
[email protected]
Media Contact
Jessica Friedeman, Chief Marketing and Product Officer
[email protected]